NeuroSearch halts NS2389 Phase II testing

NeuroSearch (CSE:NEUS) and partner Glaxo (GLX; LSE:GLXO) voluntarily suspended Phase II testing of NS2389 ( GW650250A), a small molecule blocker of active uptake of serotonin, dopamine and noradrenaline, based on preclinical animal toxicology data that NEUS said was inconsistent with previous results. The partners will conduct additional preclinical studies, which NEUS said should be completed within 6 months, before continuing clinical testing. NEUS said that the compound has been well tolerated in its completed clinical studies. ...